Pharmaceutical Preparations
Industry (SEC)
Show active companies only

733 companies

ETNB
89bio, Inc.
89bio, Inc.
California
NASDAQ
NMTR
9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc.
North Carolina
NASDAQ
ACIU
AC Immune SA
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases.
Switzerland
NASDAQ
ACAD
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc.
California
NASDAQ
ADCT
ADC Therapeutics SA
ADC Therapeutics SA is a clinical-stage biotechnology company, which develops antibody drug conjugates.
Switzerland
NYSE
ADTX
ADiTx Therapeutics, Inc.
ADiTx Therapeutics, Inc.
California
NASDAQ
AEON Biopharma, Inc.
California
AMAG
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Massachusetts
NASDAQ
ANIP
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc.
Minnesota
NASDAQ
ASLN
ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage oncology and immunology focused biopharma company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe.
Singapore
NASDAQ
AVEO
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Massachusetts
NASDAQ
ABBV
AbbVie, Inc.
AbbVie, Inc.
Illinois
NYSE
ABT
Abbott Laboratories
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Illinois
NYSE
ABEO
Abeona Therapeutics, Inc.
Abeona Therapeutics, Inc.
New York
NASDAQ
ABP
Abpro Corp
Massachusetts
ACST
Acasti Pharma, Inc.
Acasti Pharma, Inc.
Quebec, Canada
TSXV
ACCP
Accelerated Pharma, Inc.
Illinois
NASDAQ
ACRX
AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc.
California
NASDAQ
AKAOQ
Achaogen Inc
Achaogen, Inc.
California
NASDAQ
ACHN
Achillion Pharmaceuticals Inc
We are a clinical-stage biopharmaceutical company focused on advancing our oral small molecule complement system inhibitors into late-stage development and commercialization. Each of the product candidates in our portfolio was discovered in our laboratories and is wholly owned by us. We are focusing our product development activities on complement-mediated diseases where there are no approved therapies or where significant unmet medical need persists despite existing therapies.
Connecticut
NASDAQ